Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents
| 対象疾患 | Asthma |
|---|---|
| 相 | 該当なし |
| スポンサー | University of North Carolina, Chapel Hill |
| ステータス | 完了 |
| 参加者数 | 40 名 |
| 開始日 | 2021年7月27日 |
| 完了日 | 2024年2月8日 |
| 結果公開日 | 2026年6月29日 |
概要
To study the change from baseline in IL-1β (interleukin 1 beta) concentrations in the nasal airway during acute asthma exacerbation, specifically to measure the degree of change and identify the timing of peak IL-1β concentration. This information will allow the investigators to estimate effect size and guide decisions about the optimal timing of anakinra administration for the future study.
Percentage Change From Baseline in Nasal IL-1β (pg/mL) Concentrations During Asthma Exacerbation
| All Participants | 171.4 percentage change from baseline |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca